HBI Deals+Insights / M&A/IPOs
Southern Star Research (SSR), an Australian clinical research organisation (CRO) backed by private equity firm Quadrant, has invested growth capital in Singapore-headquartered CRO Expecto Health Science.
With this investment, the two CROs will form a strategic partnership to facilitate transition for sponsors from early-phase studies in Australia and New Zealand into late-phase clinical development across key Asian markets.





